Chief Medical Officer Richard J. Benjamin of Cerus Corp (NASDAQ: CERS) sold 101,740 shares of the company's common stock on March 12, 2026, according to a filing with the Securities and Exchange Commission. The total proceeds from the disposal were $168,603, with execution prices reported in the range of $1.62 to $1.73 per share.
Following the sale, Benjamin retains direct ownership of 777,361 Cerus shares. The filing includes a footnote indicating the disposition was undertaken to satisfy statutory tax withholding obligations and to cover brokerage fees associated with the vesting of restricted stock units.
Market data cited alongside the filing show Cerus shares trading at $1.80, a level that represents roughly a 7% decline over the past month but a 43% gain over the prior six months. An independent firm analysis referenced in the filing places a Fair Value estimate for the stock at $2.12 and lists the name among equities identified as potentially undervalued.
Separately, Cerus released its fourth-quarter 2025 results, reporting revenues of $233.8 million. That top-line figure exceeded projections and marked a 16% increase compared with the same quarter a year earlier. Reported earnings per share for the period stood at -$0.01, in line with market expectations.
The company also disclosed a planned leadership transition. Vivek Jayaraman, currently serving as chief operating officer, is slated to assume the roles of president and chief executive officer effective July 1, 2026. Upon his appointment he will join Cerus' board of directors. William Obi Greenman, the incumbent CEO, will become executive chairman of the board.
Investors seeking additional detail are pointed to Cerus' Pro Research Report and related analysis available through the firm's published research offerings, including noted ProTips addressing the stock's volatility. The SEC filing and the company's reported financial results provide the basis for the transaction disclosure and the corporate update.
Contextual note: The sale by an executive to meet tax and fee obligations tied to vested restricted stock units is presented in the filing as a non-discretionary transaction related to compensation mechanics rather than an open-market decision unconnected to vesting requirements.